RARS1 and cancer: Among the identified enriched sequences, significant predicted binding was associated with PITX2 (a core TE transcription factor, 217 hits; P = 1.2 × 10−7 and P of alignment = 0.0001) (Fig. 3D; Bai et al. 2012) and several nuclear receptors including RARs (63 sites; P = 0.016 and P of alignment = 0.00068), which elicit epigenetic control of stem cell differentiation and RXRB (63 sites; P = 0.016 and P of alignment = 0.00068), which results in DNA hypomethylation in cancer (Supplemental Table S5; Wang et al. 2019).